multiple sclerosis

multiple sclerosis

A new study shows that when specific human brain cells are transplanted into animal models of multiple sclerosis and other white matter diseases, the cells repair damage and restore function.

FDA-approved drug prevents myelin loss and alleviates symptoms of MS by enhancing innate cellular protective response.

NIH-funded study identifies over-the-counter compounds that may replace damaged cells

The metabolite of a drug that is helping patients battle multiple sclerosis appears to significantly slow the onset of Parkinson’s disease, researchers say.

UC Riverside study could lead to the development of drugs aimed at reducing seizures in multiple sclerosis, potentially benefiting epilepsy patients as well.

A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience.

A team of investigators at Brigham and Women’s Hospital (BWH) and the National Institute of Neurological Disorders and Stroke (NINDS) has launched a study of individuals at risk for multiple sclerosis (MS). By focusing on first-degree family members of MS patients, the research team seeks to better understand the sequence of events that leads some people to develop the disease.

UC Riverside-led mouse study shows the ligand indazole chloride improves motor function, imparting therapeutic benefits even when treatment is initiated at the peak of disease.
 

Pages